GUIDANCE DOCUMENT
Size of Beads in Drug Products Labeled for Sprinkle Rev.1 Guidance for Industry May 2012
- Docket Number:
- FDA-2011-D-0021
- Issued by:
-
Guidance Issuing OfficeCenter for Drug Evaluation and Research
This guidance provides applicants preparing or submitting new drug applications (NDAs), abbreviated new drug applications (ANDAs), and biologics licensing applications (BLAs) the Center for Drug Evaluation and Research’s current thinking on appropriate size ranges for beads in drug products that are labeled to be administered via sprinkling (e.g., capsules or packets containing beads).
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2011-D-0021.